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Tabaco y COVID-19. ¿Se reducirá su consumo después de la 
pandemia?





The severe acute respiratory syndrome type 
2 coronavirus or SARS-CoV-2, widely known 
as COVID-19, is affecting millions of people 
worldwide and causing thousands of deaths. In 
addition, this type of coronavirus could have 
a greater impact on people who have or have 
had problems with drug use such us tobacco.
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RESUMEN
El coronavirus del síndrome respiratorio agu-
do severo tipo 2 o SARS-CoV-2, ampliamente 
conocido como COVID-19, está afectando a 
millones de personas en todo el mundo y cau-
sando miles de muertes. Además, este tipo de 
coronavirus podría tener un mayor impacto en 
las personas que tienen o han tenido problemas 
con el uso de drogas como el tabaco.
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People with substance use problems may be 
more likely to experience emotional distress 
during quarantine. On the other hand, peo-
ple with more emotional distress are at greater 
risk of developing addiction during this time of 
health crisis.
It is important for people who have successfu-
lly stopped using drugs and other substances to 
maintain their motivation and seek new strate-
gies to maintain healthy routines and prevent 
relapses, as confinement measures can lead to 
stress and emotional difficulties. 
One of the most widely used legal drugs in the 
world is tobacco. Smokers are more vulnerable 
to infection by any virus (1,2) and are more li-
kely to develop chronic obstructive pulmonary 
disease (COPD) (3). 
Recent studies show that tobacco is not protec-
tive against SARS-CoV-2 infection. Increasing 
evidence suggests that cigarette smoke stimula-
tes the lungs to produce more ACE2 (angioten-
sin-converting enzyme 2), the protein that the 
coronavirus traps and uses to enter human cells 
(4).
Increased expression of ACE2 in the lungs of 
healthy smokers has been reported (5,6). Stu-
dies in mice have established that cigarette 
smoke may trigger the expansion of a subpopu-
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lation of respiratory epithelial cells that express 
ACE2 in a dose-dependent manner (4). Active 
smokers and COPD patients have increased ex-
pression of ACE2 in the lungs (7), which could 
lead to a four-fold increased risk of developing 
severe COVID-19 (8,9).
Tobacco use is also a major risk factor for 
non-communicable diseases such as cardiovas-
cular disease, cancer, some respiratory diseases 
and diabetes, and people with these diseases 
are at increased risk of developing severe symp-
toms if they are affected by COVID-19. Opiate 
users are at greater risk of suffering complica-
tions from COVID-19 due to the effect of the 
drug on the respiratory and pulmonary systems.
WHO is cautious at this stage and states that 
there is not enough information to confirm any 
link between tobacco or nicotine and the pre-
vention or treatment of COVID-19 (10), althou-
gh there are indications that tobacco exacerba-
tes COVID-19 complications.
This could lead to a future increase in public 
awareness of the severity of this pandemic as 
there is likely to be a reduction in the number 
of people who smoke, due to fears of increa-
sed transmission of COVID-19 from themselves 
and their close relatives. We know about the 
complication of quitting smoking and nicotine 
addition, but the severe psychological impact 
that COVID-19 may have caused the death of a 
family member may generate shock and greater 
fear in the subject who smokes, leading to a 
decrease in consumption.
In the meantime, in this field of drugs, especia-
lly in one of the most common such as tobac-
co, high quality and ethically approved studies 
and research should continue to be carried out 
that will contribute to improving individual and 
public health. Likewise, prevention campaigns 
aimed at the entire population must continue to 
be promoted.
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